Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.
Scientists have developed a blood test that could help pair cancer patients with the most suitable therapy for their disease, then track disease progression to see if the treatment is effective.
Patients with newly diagnosed cancer were less likely to participate in clinical trials if their annual household income was less than $50,000.
Cancer trial participation decreases with decreasing annual household income, according to recent data.
Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.
An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.
ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.
Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.
A recent study showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients who ultimately take the drugs, raising questions about the direct applicability of trial data.
Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.
Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung CancersSeptember 28, 2015
Pembrolizumab, an immunotherapy drug that unmasks cancer cells allowing the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study presented at the 16th World Conference on Lung Cancer.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
A new technique has been developed by statisticians to help doctors optimize dosing new cancer treatments in phase I/II clinical trials.
A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.
Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Personalized melanoma vaccines can be used to galvanize a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.
Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
New evidence indicates that combining chemotherapy with radiation therapy may be the best option for people with a low-grade form of brain cancer.
A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .
The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
- Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme
- New Blood Test Improves Screening for Prostate Cancer
- Nanoliposomal Irinotecan Extends Survival in Metastatic Pancreatic Cancer
- S-1 as First-line Chemo for HER2- Metastatic Breast Cancer
- Blood Sample Offers a New Way of Detecting Cancer
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Rates of PSA Screening and Early Stage Prostate Cancer Are Declining
- Use of Genomic Testing in Breast Cancer Has Greater Impact on Treatment, Costs
- Timing Matters for Pegfilgrastim Administration
- Estrogen Plus Progestin Use Increases ER+ Breast Cancer Risk in African American Women
- CSF1R Inhibition May Ease Debilitating Adverse Event of Ovarian Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|